scholarly journals The prognostic value of TCF1+CD8+T in Primary Small Cell Carcinoma of the Esophagus (PSCCE)

2021 ◽  
Author(s):  
Lin Ma ◽  
Lijun Sun ◽  
Kaikai Zhao ◽  
Zhengxin Dong ◽  
Zhaoqin Huang ◽  
...  
2019 ◽  
Vol 10 (10) ◽  
pp. 1913-1918 ◽  
Author(s):  
Nan Wang ◽  
Xue Li ◽  
Hui Luo ◽  
Yanan Sun ◽  
Xiaoli Zheng ◽  
...  

2019 ◽  
Author(s):  
Nan Wang ◽  
Xue Li ◽  
Hui Luo ◽  
Yanan Sun ◽  
Xiaoli Zheng ◽  
...  

Abstract Background: Growing evidence indicates that several inflammatory biomarkers may predict survival in patients with malignant tumors. The aim of this study is to evaluate the prognostic value of pretreatment biomarkers in patients with primary small-cell carcinoma of the esophagus(PSCCE). Methods: There were 73 PSCCE patients enrolled between January 2009 and December 2017 at the Affiliated Cancer Hospital of Zhengzhou University. The total lymphocyte counts (TLC), neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) prior to anticancer therapy were collected as inflammation biomarkers. The cut-off value was determined by Receiver operating characteristic (ROC). The Kaplan–Meier method was utilized to analysis overall survival (OS). Cox proportional hazards regression was used to identify univariate and multivariate prognostic factors. Results: Univariate analysis showed that high NLR group(hazard ratio (HR) =1.685; 95% CI: 1.001–2.838; P=0.047) and high PLR group (hazard ratio (HR) =1.716; 95% CI: 1.039–2.834; P=0.033) were associated with poor OS, and TLC was not correlated with OS. On multivariate analysis, high PLR(hazard ratio (HR) =1.751; 95% CI: 1.042–2.945; P=0.035) was an independent prognostic factor of unfavorable OS. Conclusions: Pre-treatment PLR and NLR are correlated with OS. These biomarkers are easily accessible, cost effective, and can serve as a marker to identify high-risk patients for further designing personalized treatment and predicting treatment outcomes.


2020 ◽  
Vol 2 (Supplement_3) ◽  
pp. ii19-ii19
Author(s):  
Masataka Mikai ◽  
Mitsuyoshi Abe ◽  
Yo watanabe ◽  
Chie Nakada ◽  
Yutaka Huchinoue ◽  
...  

Abstract Brain metastases from esophageal cancer is rare and the incidence has been reported at approximately 5%. We report a case of brain metastases with repeated bleeding from Esophageal carcinoma. The case is a 76-year-old man. Three years ago he was diagnosed with small cell carcinoma of the esophagus by endoscopic biopsy. Metastasis was found only in the cervical lymph node, but the condition was stable by chemoradiotherapy and no metastases were found throughout the body before 1 month. He was admitted to the hospital because of a sudden convulsion, and CT scan revealed cerebral hemorrhage in the right frontal lobe. We performed conservative treatment, but rebleeding was observed from the same site repeatedly after 1 month and 2 months. Due to the influence of bleeding, it was difficult to distinguish cerebral hemorrhage from brain tumor by contrast MRI. After surgery, the cause of bleeding was diagnosed as metastatic brain tumor of esophageal small cell carcinoma. Postoperative radiation therapy was performed in another hospital, but rebleeding was observed 3 months after the operation. A reoperation was performed at another hospital, and a recurrence of metastatic brain tumor was diagnosed. In the case of highly malignant metastatic brain tumors, it was considered necessary to frequently follow the images.


2014 ◽  
Vol 28 (5) ◽  
pp. 476-482 ◽  
Author(s):  
M. R. Xie ◽  
S. B. Xu ◽  
X. H. Sun ◽  
L. Ke ◽  
X. Y. Mei ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document